Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen.
We have isolated an anti-idiotypic mAb (RS1.1.3), which recognizes an idiotope present on several IgM mAb specific for Moloney murine leukemia virus (M-MuLV)-determined cell surface Ag. The binding of RS1.1.3 to idiotypic antibody could be inhibited by specific Ag. Intraperitoneal immunization of mice with purified RS1.1.3 antibody-induced effective immunity against Moloney murine sarcoma virus challenge. A single injection of RS1.1.3 7 days before virus challenge resulted in a 27% reduction in tumor load compared to non-immune control mice challenged with the same dose of virus, whereas multiple injections of RS1.1.3 before virus challenge resulted in a 75% reduction in tumor load. The protective effect of anti-idiotype immunization appeared to be T dependent, because immunization of athymic mice had no effect on their susceptibility to tumor virus challenge. Administration of the anti-idiotypic antibody after virus inoculation caused an increase in tumor load of nearly 50% compared to non-immune controls. BALB/c mice immunized with RS1.1.3 developed anti-anti-idiotypic antibodies, as well as M-MuLV Ag-specific antibodies. Analysis of sera from RS1.1.3-immune mice subsequently challenged with Moloney murine sarcoma virus indicated an inverse relationship between tumor load and M-MuLV-specific serum IgG titers induced by the RS1.1.3 immunization. These results indicate that anti-idiotypic mAb may be used as immunogen to induce Ag-specific antibody responses, and to cause effective immunity to a retro-virus-induced tumor.
Powell
T J
TJ
Birmingham Veterans Administration Medical Center, Department of Surgery, AL.
Spann
R
R
Nguyenduc
M
M
Lamon
E W
EW
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage* / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000032:analysis; D000918:Antibody Specificity; D000956:Antigens, Viral / Q000008:administration & dosage*; D001666:Binding Sites, Antibody; D001667:Binding, Competitive; D005260:Female; D007106:Immune Sera / Q000032:analysis; D007113:Immunity, Innate; D007130:Immunoglobulin Idiotypes / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008980:Moloney murine sarcoma virus / Q000276:immunology*; D009053:Sarcoma Viruses, Murine / Q000276:immunology*; D012513:Sarcoma, Experimental / Q000276:immunology*
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000956:Antigens, Viral; D007106:Immune Sera; D007130:Immunoglobulin Idiotypes